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Ultrasound-enhanced ocular delivery of
dexamethasone sodium phosphate: an in vivo
study
Marjan Nabili1*, Aditi Shenoy1, Shawn Chawla1, Sankaranarayana Mahesh2, Ji Liu2, Craig Geist2 and Vesna Zderic1

Abstract
Background: The eye's unique anatomy and its physiological and anatomical barriers can limit effective drug
delivery into the eye.
Methods: An in vivo study was designed to determine the effectiveness and safety of ultrasound application in
enhancing drug delivery in a rabbit model. Permeability of a steroid ophthalmic drug, dexamethasone sodium
phosphate, was investigated in ultrasound- and sham-treated cases. For this study, an eye cup filled with
dexamethasone sodium phosphate was placed on the cornea. Ultrasound was applied at intensity of 0.8 W/cm2
and frequency of 400 or 600 kHz for 5 min. The drug concentration in aqueous humor samples, collected 90 min
after the treatment, was determined using chromatography methods. Light microscopy observations were done to
determine the structural changes in the cornea as a result of ultrasound application.
Results: An increase in drug concentration in aqueous humor samples of 2.8 times (p < 0.05) with ultrasound
application at 400 kHz and 2.4 times (p < 0.01) with ultrasound application at 600 kHz was observed as compared to
sham-treated samples. Histological analysis showed that the structural changes in the corneas exposed to
ultrasound predominantly consisted of minor epithelial disorganization.
Conclusions: Ultrasound application enhanced the delivery of an anti-inflammatory ocular drug, dexamethasone
sodium phosphate, through the cornea in vivo. Ultrasound-enhanced ocular drug delivery appears to be a
promising area of research with a potential future application in a clinical setting.
Keywords: Therapeutic ultrasound, Drug delivery, Cornea, Ocular diseases, Sonophoresis, Dexamethasone sodium
phosphate

Background
The objective of this study was to investigate the role
of ultrasound in enhancing delivery of an ocular antiinflammatory drug, dexamethasone sodium phosphate,
through the cornea in a rabbit eye model in vivo. Ultrasound has been used in ophthalmology for decades but
mostly as a diagnostic imaging tool [1]. For example,
ultrasound biomicroscopy imaging can provide highresolution imaging of the anterior part of the eye [2].
Therapeutic ultrasound also has a potential for clinical
applications in ophthalmology [3]. High-intensity focused
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ultrasound (HIFU) has been reported as an effective treatment method for reducing intraocular pressure, which
showed promising results in both animal and clinical studies as a potential novel approach for glaucoma treatment
[4-6]. Sonoda et al. [7] used ultrasound in conjunction
with commercially available microbubbles to enhance
gene delivery into the back of the eye of New Zealand albino rabbits without any ocular tissue damage observed
and with 1.5 to 2 times increase in the delivery efficiency.
The application of therapeutic ultrasound at frequency of
690 kHz has also been observed as effective in moderately
disrupting the integrity of the blood retinal barrier when
applied as 10 ms bursts of 1 Hz for 60 s at pressures of up
to 1.1 MPa, thus increasing the penetration of systemically
administered drugs into the retina [8].

© 2014 Nabili et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
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The eye's distinct anatomy and physiology pose challenges to the development of effective ocular drug delivery
systems [9] since its various defense mechanisms make it
very difficult to achieve sufficient drug penetration into
the eye [3,10]. Topical administration of drugs into the
eye is convenient, common, and well accepted by patients
[9,11]. However, this method is highly inefficient because
only 1%–5% of the applied ocular drug penetrate to the
desired ocular site [11,12]. Most of the topically administrated drugs are washed away by factors such as normal
tear volume, blinking, induced lacrimation [12], and nasolachrymal drainage [9,11,12]. Moreover, drugs can enter
systemic circulation through conjunctival blood capillaries
and lymphatics before reaching intraocular tissues [12,13].
The cornea is considered to be the main pathway for topical drug delivery [3,10]; however, the passage of ocular
drugs is limited by corneal barriers [9-11]. This highly
selective barrier consists of three primary layers: namely,
the epithelium, which is impermeable to hydrophilic drugs
because of its lipophilic properties and tight junctions;
the stroma, which is hydrophilic in nature, making it a
dominant barrier for lipophilic drugs; and the endothelium [14,15]. Intravitreal and periocular injections are
some of the invasive methods of ocular drug delivery,
which are used to avoid inefficient topical and systemic
processes. However, these methods have their own side effects including infection and cataract formation [3]. Many
other methods such as hydrogel contact lenses, mucoadhesive and viscosity-enhancing polymers, iontophoresis,
liposomes, and nanoparticles have been used to increase
concentration of the drugs delivered into the eye [12,13].
For example, hydrogel contact lenses can increase the bioavailability of drugs by prolonging the drug exposure time.
However, these contact lenses can cause blurring of vision
and local corneal tissue toxicity [16,17]. Ocular iontophoresis, while effective in delivering drugs, requires
specialized drug formulations and was shown to have
mild adverse effects [18]. This noninvasive technique
involves applying a small electric current to enhance
the penetration of ionized drug into the eye [9] and has
been investigated for delivering different types of ocular
drugs such as antibiotics [19] and anti-viral drugs [20].
Injectable biodegradable implants in the forms of rods,
plugs, discs, or sheets have also been proposed for ocular
drug delivery; however, this approach is expected to have
low patient compliance due to its invasive nature [21].
The design of our study focused on promoting topical
drug penetration through the cornea via ultrasound
methods, potentially providing a way for topical ophthalmic drugs to reach different areas in the eye more effectively. Our approach may allow for better targeting of
diseased eye tissues as compared to systemic methods,
leading to usage of smaller quantities of the drug to get
the desired therapeutic effect and to reduce toxicity of
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the treatment. In addition to delivery of commercially
available ophthalmic drugs, other compounds such as
macromolecules that may assist with wound repair have
the potential to be coupled with ultrasound-mediated
delivery [22]. Wound repair in the body is normally
dependent on the presence of vasculature for the delivery
of nutrients to damaged tissue; however, many of the eye's
translucent structures are avascular (e.g., cornea, lens,
vitreous). When damaged, these tissues do not have access to thrombospondin 1, a glycoprotein central to tissue
repair, and as a result fibrosis and repair are slow, causing
scarring of eye tissue and thus blindness [23].
Results from our previously performed in vivo studies
showed that using 880-kHz ultrasound at intensities of
0.19, 0.34, and 0.56 W/cm2 (in a continues mode) with
an exposure duration of 5 min resulted in 2.4, 3.8, and
10.6 times increases in corneal permeability respectively
for a drug mimicking dye sodium fluorescein [24]. Similar
results were also reported by Nuritdinov [25] who showed
that ultrasound at frequencies of 470–880 kHz and intensity of 0.3 W/cm2 applied for 5 min produced up to
ten times increase in the corneal permeability for sodium fluorescein in a rabbit model, in vivo.
The main goal in the study reported here was to investigate the corneal permeability for a clinically relevant
anti-inflammatory drug, dexamethasone sodium phosphate, in an in vivo model, which can give us a better
understating of an actual clinical situation. After investigating the effects of ultrasound application on the delivery of dexamethasone sodium phosphate in vitro [26],
we decided to focus on the ultrasound parameters found
optimal in these in vitro studies and utilize them in our
in vivo studies.

Methods
A total of 20 healthy New Zealand white rabbits, 1–2 years
old, were used in our studies. Rabbit eyes have been
used as the standard model for ophthalmic drug delivery research [14,27,28]. All procedures were performed
in accordance with Institutional Animal Care and Use
Committee (IACUC) regulations under the approved
protocol. The entire experiment was completed in the
animal facility at the George Washington University in
the span of two nonconsecutive days. An attending veterinarian assisted our research team with anesthesia
and animal handling procedures. Rabbits were anesthetized with injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). Anesthesia was reapplied as needed as
determined by the veterinarian.
In vivo experiment

The rabbits were randomly assigned to three groups:
ultrasound treatment at 400 kHz (n = 6), ultrasound
treatment at 600 kHz (n = 6), and sham treatment group
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(n = 8). The sham treatment experiments were set up
exactly the same as ultrasound-treated experiments. Ultrasound transducer was submerged inside the solution in
eye cup, and all of the procedures were the same (except
that the ultrasound power button was not turned on).
In all cases, only one of the rabbit's eyes received the
treatment. The other eye was used as a control where
no ultrasound application or drug exposure was present.
These control eyes were used for histological observations.
The ophthalmic drug used in our experiments was dexamethasone sodium phosphate, which had also been used
during our previous in vitro studies [26]. Dexamethasone
sodium phosphate is used in ophthalmology as a 0.1%
topical steroid solution (Bausch & Lomb Inc, Tampa,
FL, USA) applied in the treatment of inflammatory conditions. It has a molecular weight of 516.41 Da and
hydrophilic properties.
Unfocused circular ultrasound transducers (Sonic
Concepts, Bothell, WA, USA) with 15-mm active diameters were used in the experiments and were positioned
at near to far field transition distance from the eye to ensure optimal energy delivery. The transition point from
the near field to the far field, dff, is the location of the
furthest maximum pressure for the unfocused transducer [29]. These transducers operated at frequencies of
400 and 600 kHz, and the dff calculated for each transducer frequency was 1.5 and 2.25 cm, respectively. The
driving unit consisted of a function generator (33250,
Agilent, Santa Clara, CA, USA) connected to the power
amplifier (150A100B, Amplifier Research, Souderton, PA,
USA), which was connected to the ultrasound transducer
via an electrical power meter (Sonic Concepts, Bothell,
WA, USA).
The eye cup was designed in such a way that it could
hold up to 25 mL of solution by adding an extension
above the standard eye cup area as shown in Figure 1.
This extension was added to ensure that the transducers
would be submerged in the drug solution while still held
within the dff distance from the corneal surface. A metal
xstand was placed inside the eye cup to secure the

original
eye cup

metal
stand

extension
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transducers in place and keep them at dff distance from
surface of the cornea during ultrasound and sham treatments. Ultrasound transducer was submerged in the
drug solution inside the eye cup during the experiment.
During treatment, therapeutic ultrasound was applied
at the parameters that were shown most effective in our
previous in vitro studies. The in vitro results specifically
showed that using lower frequency ultrasound (in the
400 kHz to 1 MHz range) was more effective in increasing
the permeability of the cornea [26]. The ultrasound intensity used in the in vivo studies was 0.8 W/cm2, and duration of ultrasound application was 5 min. The ultrasound
transducers and the eye cup were rinsed with saline before
procedure. The eye cup (Figure 2) was placed under the
rabbit eyelid and filled with the drug solution after the
animal was anesthetized. Ultrasound application started
immediately after the eye cup was placed on the eye and
filled with the drug solution. The transducer with the
active diameter of 15 mm covered the entire surface of
the cornea which had a diameter of 14–15 mm. After
5 min, ultrasound application was stopped and the transducer and the drug solution were removed from the eye
cup, followed by a careful removal of the eye cup from the
animal. The eye was not rinsed afterwards.
The solution was kept at room temperature (approximately 25°C) before the starting of the experiments. The
temperature of drug solution inside the eye cup in the
proximity of the cornea was measured (Figure 3) during
ultrasound application using a thermometer (dual thermometer, Fisher Scientific, Atlanta, GA, USA). The thermocouple used was a K type with approximately 1-mm
width. The thermometer was not touching the cornea
to prevent accidental damage. Temperature was recorded
at initial (t = 0 min), midpoint (t = 2.5 min), and final
(t = 5 min) times after the start of ultrasound application.
After ultrasound application, in vivo gross observation
of the cornea was performed using a high-magnification
stereomicroscope. This procedure was repeated after
80 min from the start of the experiment, before the animal
was euthanized.
At approximately 90 min after the ultrasound treatment, the animal was euthanized (using Euthasol at
1 mL/4.54 kg) and 0.3 mL sample of the aqueous humor
was collected subsequently using a 27 G × 1/2 in. needle
(12.7 mm length). The aqueous humor samples were
stored in a freezer at −80°C. Once the aqueous humor
was sampled, the eyes were excised and the cornea was
dissected and fixed in formalin (Protocol®, Fisher Scientific
Company, Kalamazoo, MI, USA).
Histology

Figure 1 Eye cup design. Original and modified eye cup used in
in vivo experiments.

The cornea samples were prepared using hematoxylin
and eosin (H & E) staining procedures for histology
slides (Histoserv, Inc., Germantown, MD, USA). In our
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Figure 2 In vivo setup. (a) The eye cup and transducer placement. (b) Close-up of the eye cup placement on the rabbit eye in vivo.

previous in vitro studies [26], we developed a procedure
for the determination of changes in the epithelial layer
of the cornea, where corneas were classified into four
groups based on the level of epithelial damage. Each
class was given a value of 0, 1/3, 2/3, or 1 (please see
Figure 2 from Nabili et al. [26]). Class 0 (value of 0) has
no epithelial disorganization (all cells appear intact; the
layers of epithelium are well organized). Class 1 (value
of 1/3) has minor epithelial disorganization (some of
the cells appear necrotic; some cells are missing or the
first layer of epithelium is removed). For class 2 (value
of 2/3), a more severe epithelial disorganization is observed (more cells appear necrotic or missing; cells in the
two to three layers of epithelium appear damaged). Class 3
(value of 1) has the most severe epithelial disorganization
(majority of the cells are ruptured; all of the epithelial
layers are absent or severely damaged).
The thickness of the different layers of the cornea (epithelium, stroma, and endothelium) was also determined
from the histological slides. To determine the thickness,
measurements of the width of each layer, were performed
at the same three locations on each sample. Each cornea
sample was examined using Zeiss AxioImager light microscope (Carl Zeiss, Jena, Germany) at × 5–20 magnification.
The three locations that were measured on each cornea
sample were at the center of the cornea (location 1),

Thermometer

Transducer

Eye cup
Ophthalmic solution
Cornea
Eyelid

Figure 3 Schematic of in vivo setup. Placement of the thermocouple
and transducer with respect to the eye.

midway between the left end of the cornea and the center
(location 2), and midway between the right end of the
cornea and the center (location 3). These measurements
were reported in micron. If any of the corneal layers
were missing, they were recorded as ‘absent’ and were
shown in calculations as a ‘0’ value.
Chromatography

Aqueous humor samples were sent to a facility (Cayman
Chemical Co., Ann Arbor, MI, USA), which used chromatography methods to investigate the amount of dexamethasone sodium phosphate inside sham- and ultrasound-treated
samples. A calibration curve for dexamethasone sodium
phosphate was first generated, followed by the determination of the amount of dexamethasone sodium phosphate
in aqueous humor samples. Two out of twenty samples
sent to the facility were not analyzed due to inadequate
amounts of aqueous humor in these samples.
Based on the protocol provided by this chromatography
facility, the procedure to generate calibration curves for
dexamethasone and measuring amount of dexamethasone
in an aqueous humor sample is explained as follows: to
create the calibration curve for dexamethasone, 10 μL of
dexamethsone calibration standard solution (100 μg/mL)
was added to a microcentrifuge tube with 990 μL of
95:5 (v/v) water/acetonitrile, vortex mixed for about 15 s,
and subsequent 500 μL serial dilutions were made. Fifty
microliter of dexamethasone-d4 internal standard solution
was added to 100 μL of each standard and vortexed for approximately 15 s; 1 mL of methyl tert-butyl ether (MTBE)
was added to each and vortexed for about 15 s and then
centrifuged for 10 min. The organic layer was transferred
to a 1.5-mL auto-sampler vial and dried under nitrogen
and reconstituted with 100 μL of 95:5 (v/v) water/
acetonitrile. To investigate the amount of dexamethasone
inside the aqueous humor sample from our experiments, 10 μL of sample with unknown concentration of
dexamethasone sodium phosphate and 90 μL of water
were added to a microcentrifuge tube, and 50 μL of
dexamethasone-d4 internal standard solution was added
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to one 100 μL of each standard and vortexed for about
15 s. One milliliter of MTBE was added to 46 each, vortexed about 15 s, and centrifuged for 10 min. The organic
layer was transferred to a 1.5-mL auto-sampler vial and
dried under nitrogen and reconstituted with 100 μL of
95:5 (v/v) water/acetonitrile.

Drug Concentration (ng/mL)

Results
The statistical test used to analyze the data was a t-test:
two-sample assuming unequal variances. Figure 4 shows
the comparison between the dexamethasone sodium phosphate concentration in aqueous humor in ultrasoundtreated and sham-treated samples. The increase in drug
concentration in aqueous humor samples was 2.8 times
(p < 0.05) at ultrasound frequency of 400 kHz (n = 5) and
2.4 times (p < 0.01) at frequency of 600 kHz (n = 6), when
compared to sham-treated samples (n = 7). Drug concentration increase in the eye in case of sham-treated samples
was 593.8 ± 351.9 ng/mL. This value was 1,658.5 ± 823 ng/
mL using 400-kHz frequency and was 1,453.8 ± 434.3 ng/
mL using 600-kHz-frequency ultrasound.
No gross damage of the cornea was detected using
stereomicroscopy observations immediately after the
treatment and 80 min after the treatment. In subsequent histological observations, ultrasound-induced
changes were observed in the epithelial layer of the cornea
including missing cells and in some cases detachment
of whole epithelial cell layers. No apparent changes
were observed in the stroma and endothelium; however,
detachment of the endothelium was observed in some
sham-treated and ultrasound-treated samples and may
be caused by processing artifacts [30,31]. Representative
light microscopy images of control, sham-treated, and
ultrasound-treated corneas are shown in Figure 5. Results
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of histological analysis of ultrasound- and sham-treated
corneas based on the four classes of epithelial damage, as
described in the ‘Methods’ section, are shown in Figure 6.
The increase in the epithelial damage was four times
(p < 0.01) at ultrasound frequency of 400 kHz (n = 6)
and three times (p < 0.05) at frequency of 600 kHz (n = 6),
as compared to sham-treated samples (n = 8).
The quantitative changes in the corneal structure
was 0.25 ± 0.46 in sham-treated samples, 1.7 ± 0.51
using 400-kHz frequency, and 1.0 ± 0.63 using 600-kHzfrequency ultrasound. These values are calculated based
on the characteristic model designed to analyze corneal
damage in semi-quantitative matter (see ‘Methods’ section).
Despite the fact that aqueous humor samples from all
eyes were sent to a chromatography facility, the amount
of drug in one sample from 400-kHz batch and one from
sham-treated batch was not investigated due to inadequate
amount of samples for the equipment. However, all cornea
samples which were sent to a histological facility were
processed. For these reasons, there is a difference between
samples of aqueous humor and cornea samples used for
histology analysis.
Figure 7 shows thickness of different layers of cornea in
ultrasound- and sham-treated samples. The mean thickness of ultrasound-treated epithelium was smaller as compared to control and sham-treated cases. For 400-kHz
ultrasound exposure, changes in the epithelial thickness
were observed as 57% (p < 0.001) decrease as compared to
control epithelium and 49% decrease as compared to
sham-treated samples (Figure 7a). For 600-kHz ultrasound
treatments, apparent decrease in the epithelial thickness
was 33% as compared to control samples and 19% as
compared to sham-treated samples (with no statistical
significance) (Figure 7a). The thickness of the ultrasound-

3000
n=5

**

2500

n=6

*

2000
1500
n=7

1000
500
0

Sham

400 kHz

600 kHz

Figure 4 Dexamethasone sodium phosphate concentration in aqueous humor. Dexamethasone sodium phosphate concentration increased
in aqueous humor as a result of ultrasound application as compared to sham-treated samples (n = 7). Ultrasound was applied at frequencies of
400 kHz (n = 5) and 600 kHz (n = 6), intensity of 0.8 W/cm2, and exposure duration of 5 min. Data are given as mean ± standard deviation.
*p value <0.05, **p value <0.01.
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a

b

c

d

Figure 5 Histology analysis. (b) A control cornea, (b) a sham-treated cornea, (c) a corneal sample exposed to 400-kHz ultrasound, and (d) a
corneal sample exposed to 600-kHz ultrasound. The epithelium is the eosinophilic layer, indicated by white arrow, as opposed to much thinner
endothelium, which is just a cell layer in thickness, marked with a black arrow. Magnification of × 10 was used.

1

Epithelial Damage

0.9
0.8
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n=6

0.6
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n=6
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0.4
0.3
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n = 20

n=8

0.1
0

Control
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Figure 6 Change in the corneal structure. Changes in the cornea as a result of ultrasound application as compared to sham-treated corneas
(n = 8). Different bars represent the corneal damage due to ultrasound application at frequencies of 400 kHz (n = 6) and 600 kHz (n = 6). Data are
shown as mean ± standard deviation. No changes were observed in control corneas (n = 20) in all cases. *p value <0.05; **p value <0.001.
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Figure 7 Thickness of different layers of the cornea. This graph shows thickness of the different layers of the cornea: (a) epithelium, (b) stroma,
and (c) endothelium. Different bars represent results for control, sham-treated, 400- and 600-kHz-ultrasound-treated samples. *p value <0.05 as
compared to sham values; **p value <0.001 as compared to control values.

treated stroma was not significantly different from control
and sham-treated stroma (Figure 7b). Endothelial thickness
appeared to decrease to 10% for sham-treated samples
as compared to controls with no statistical significance.
Comparison between sham-treated and ultrasound-treated

endothelium showed 41% decrease (p < 0.05) and 30%
decrease for 400 and 600 kHz, respectively (Figure 7c).
Figure 8 shows the relation between drug concentration
in the aqueous humor and the corneal damage as calculated based on the four classes of epithelial damage
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Drug Concentration (ng/mL)
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Figure 8 Relation between drug concentration in aqueous humor and corneal damage. This figure shows a relationship between corneal
damage and drug concentration in the aqueous humor for ultrasound- and sham-treated cases. Data are given as mean ± standard deviation.

(as shown in Figure 6). There appears to be a direct relation between the drug concentration increase and the
level of corneal damage.
The change in temperature from t = 0 to t = 5 min for
sham-treated cases was 0°C–3°C (mean ± standard deviation of 1.4°C ± 1.2°C). In ultrasound-treated cases, the
change of temperature for the same period of time was
3°C–6°C (mean ± standard deviation of 4.0°C ± 1.1°C) for
400-kHz ultrasound and 4°C–5°C (mean ± standard deviation of 4.8°C ± 0.4°C) for 600-kHz ultrasound.

Discussion
The potential advantages of using ultrasound for drug,
gene, and protein delivery, using parameters that cause
cavitation and streaming effects, have been confirmed in
different experimental studies [24,28,32]. Cavitation is
known as the creation, oscillation, and collapse of gas
bubbles due to acoustic waves [33-35]. It is stated to be
the main mechanism responsible for promoting drug
delivery through the skin [32,36]. There are two types of
cavitation: stable and inertial. Stable cavitation is defined as the uniform pulsation of bubbles over long time
intervals [33], and the oscillation of these bubbles can
produce mechanical stresses that may cause cell membrane rupture [37]. In the case of inertial cavitation, collapse of the bubbles causes shock waves and microjets
to be generated near the cells, thus producing pits in
the cell membranes [38,39]. The effect of inertial cavitation is greater at lower frequencies because bubbles
have more time to grow, which results in a more violent
collapse [40]. Based on our previous studies [24], at
ultrasound frequency of 880 kHz, cavitation activity was
shown to correlate with enhancement of drug delivery
through the cornea in vivo, and similar mechanisms are
expected here. The mechanism, which has an effect on
increasing the drug penetration through the cornea, is

thought to be cavitation and generation of bubbles. In
this study, stable cavitation appeared to be the cause of
corneal permeability enhancement in the case of ultrasound applied at 0.19 W/cm2, however; both stable and
inertial cavitation were present when higher intensities
of 0.34–0.56 W/cm2 were used [24].
There is an inverse relationship between ultrasound
frequency and cavitation effects. It is difficult to generate
cavitation at higher frequency because the time between
the positive and negative acoustic pressure is short [41].
As a result, the gas that is dissolved in a medium does
not have the ability to diffuse into the cavitation nuclei
[41]. For the purpose of this study, we chose ultrasound
frequencies of 400 and 600 kHz which belong to medium
frequency range; therefore, cavitation was one of the likely
mechanisms that cause an increase in corneal permeability. Results from our in vitro study for dexamethasone sodium phosphate showed that corneal permeability
had a statistically significant increase of 43% to 109% after
ultrasound exposure at 400 kHz (at intensity of 0.3 to
1.0 W/cm2 applied for 5 min) as compared to shamtreated samples. The increase in corneal permeability
observed in case of 400-kHz ultrasound was more effective as compared to ultrasound application at 600 kHz
(46%–55% permeability increase at intensities of 0.3 to
1.0 W/cm2), 800 kHz (50%–72% increase at intensities of
0.5 to 1.0 W/cm2), and 1 MHz (46%–63% increase at
intensities of 0.5 and 0.8 W/cm2).
In addition to cavitation effects, streaming and microstreaming may have played a role in increasing corneal
permeability. Acoustic streaming is identified as a force,
which is able to move ions and small molecules as a result of physical action of ultrasound waves [42]. Shearing
and streaming forces associated with ultrasound may
disrupt cell walls, internal organelles, and tissues if applied at high enough intensities [29]. Further, acoustic
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streaming was recognized to be an important factor in
the enhancement of drug delivery through the skin
[32,36]. When bubbles oscillate in an ultrasound field, a
microscale circulatory motion forms around the oscillating
bubble and is called microstreaming [43,44]. The shear
stresses generated by microstreaming near cell boundaries,
due to expansion and contraction of microbubbles, may
cause cell membrane rupture [37] and result in hemolysis,
release of protein from bacteria, and mechanical disruption of plant cells [37,45]. Further, microstreaming was
shown to cause an increase in the movement of blood and
fluids around the thrombus and enhance drug infusion
into the thrombus [46]. Therefore, streaming and microstreaming are important ultrasound mechanisms that have
the potential to increase drug penetration through the cornea in this study.
The epithelium, stroma, and endothelium of the cornea
each have its own unique structure, which can represent a
barrier for drug penetration into the eye [47]. The corneal
epithelium's tight junctions and its lipophilic nature act as
a barrier to hydrophilic drugs, and the stroma's highly hydrated structure limits the penetration of lipophilic drugs
[47]. Any corneal disorganization caused by ultrasound
application, which changes the structure of the first
layer of the cornea and its tight junctions, is expected to
enhance the drug penetration into the eye [26,48]. In
comparison, drug penetration through the skin also increased as ultrasound application altered the stratum
corneum and its lipid bilayer structure [32].
The in vivo study presented here is designed based on
our previously performed in vitro study, which resulted
in a statistically significant increase in the corneal permeability for dexamethasone sodium phosphate [26]. Results
from our in vitro study showed a corneal permeability increase of 2.1 times at 400 kHz and 1.5 times at 600 kHz,
at intensity of 0.8 W/cm2, as compared to sham-treated
samples. Likewise, this in vivo study showed a statistically
significant increase in drug delivery through the cornea.
The increase in corneal permeability was greater in our
in vivo study with maximum increase of 2.8 times, as compared with previous in vitro experiments [26]. In both
studies, the level of damage observed in histology slides
was limited to the epithelial layer, with no apparent
damage in the stroma and endothelium [26].
The quantity of drug used was adequate to insure submerging of ultrasound transducer tip inside the solution.
The maximum amount of drug used in the eye cup was
approximately 15 mL. There is no direct relationship between the quantity of drug used in our study and the
quantity of drug delivered locally in eye drops. In our
study, the eye was exposed to drug solution for 5 min,
which is less than the lag time (approximately 25 min)
allowing penetration of dexamethasone sodium phosphate
through the cornea. The goal of this study was not only to
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compare the eye drops and the eye cup drug application
but also to see if ultrasound can promote the drug delivery
through the cornea in vivo.
In our previous in vitro studies, the spherical head diffusion cell was used to minimize the change to the natural
shape of the eye, but this change in the eye structure as
compared to in vivo situation may have been a contributing factor—likely minor to the enhancement of corneal
permeability. Also, storing the eyes in nutrient-adjusted
storage solution after the eyes are excised can cause deterioration of corneal barrier properties [49] which may
increase corneal permeability in vitro in both ultrasoundtreated and sham-treated samples. In summary, the advantages of testing in vivo as compared to in vitro setup are
the following: keeping the natural shape and structure of
the rabbit eye, natural clearance mechanisms, perfusion,
and the fact that eye does not potentially lose its barrier
properties due to decay [49,50].
Investigating the corneal permeability of dexamethasone
sodium phosphate, using 400- and 600-kHz ultrasound
frequencies at 0.8 W/cm2 for 5 min, resulted in the enhancement of ocular drug delivery through the cornea,
which was statistically significant as compared to shamtreated samples in in vitro and in vivo studies. There are
differences in results from in vitro and in vivo studies that
may be caused by experimental setup, environmental aspects, and tissue orientation. For example, the absorption
of samples collected from receiver compartment of diffusion cells during in vitro study was measured using a spectrophotometer. The sensitivity of this device can have an
impact on the amount of drug detected. On the other
hand, sampling the actual aqueous humor from the eye in
in vivo study and measuring the drug concentration inside
this solution using chromatography methods can be more
efficient. Moreover, all the samples in both cases were
treated the same and were analyzed consistently.
In our current study, the major structural changes
were observed in the epithelial layer of the cornea. Some
of these changes included cell removal from the first
layer of the epithelium. Also some epithelial cells from
inner layers appeared lighter in color or their nucleus
were missing. The stroma and endothelium were not
damaged in most cases; however, detachment of endothelium was observed in some samples, which may be
caused by processing artifacts [30,31]. Our current findings were consistent with our previous work where based
on histological analysis, in both in vitro and in vivo corneal
samples, the ultrasound-induced changes were observed
mostly in the epithelial layers [24,26,48]. Results from our
semi-quantitative analysis (as described in the ‘Methods’
section) showed that ultrasound-induced damage in
the epithelial layers at frequency of 400 kHz was four
times higher (p < 0.01) in vivo (n = 6) and 1.8 times
higher (p < 0.01) in vitro (n = 12) as compared to respective
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in vivo and in vitro sham-treated samples (n = 8–33).
Using the same method, the damage in the epithelial
layer after application of 600-kHz ultrasound was three
times higher (p < 0.05) in vivo (n = 6), and two times
higher (p < 0.01) in vitro (n = 15) as compared to shamtreated samples (n = 8–33).
The in vitro corneas [26] are likely to have sustained
more tissue damage than the in vivo corneas since the
in vitro corneas were taken out the organism and handled.
During in vivo study, the eyes were dissected after 90 min
from the treatment and were considered as minimally
damaged. However, during in vitro study, the eyes were
shipped from a facility, which dissected the eyes approximately 20–24 h before we received them. There is a
chance that these eyes were deteriorated while in the
medium and during shipment. This factor may influence
the differences between results in vitro and in vivo. By
comparing in vivo and in vitro sham-treated corneas to
the in vivo and in vitro corneas exposed to 400- and 600kHz ultrasound, it can be determined whether the tissue
damage sustained by the experimental corneas is mainly
due to the ultrasound exposure. The in vivo corneas usually had mostly intact epithelium, stroma, and endothelium in each of the samples, while all the in vitro corneas
had large gaps in the epithelium and stroma and had fragmented or absent endothelium. Some of the in vivo corneas had more obvious tissue damage which was unlikely
due to the ultrasound application. Some of the damages
indicated above can be due to histological processing
artifacts [30,31]. Our histological analysis indicated that
exposing the corneas to 400-kHz ultrasound affected
the tissues of the corneas more significantly than exposure to 600-kHz ultrasound, in both in vitro and in vivo
cases. Results from semi-quantitative histological analysis for in vitro study showed that approximately two
times increase (p < 0.01) in the epithelial damage was
observed as compared to sham-treated samples (n = 33)
using 400 kHz (n = 12) and 600 kHz (n = 15) ultrasound
application at 0.8 W/cm2 for 5 min. Using the same
method of analysis for the same parameters in vivo
showed four times increase (p < 0.01) at frequency of
400 kHz (n = 6) and three times increase (p < 0.05) at
frequency of 600 kHz (n = 6), as compared to shamtreated samples (n = 8). From the statistical results of layer
thickness measurements, we learned that for 400-kHz
ultrasound application in vivo, the epithelium was significantly thinner (p < 0.001) as compared to control cases.
The thickness changes in the stroma due to ultrasound
application were not statistically significant. The thickness
changes in the endothelium could not be analyzed with
certainty since the endothelium was completely absent in
some samples (and thus recorded as a value of 0), and
this absence may have been due to histology processing
artifacts as mentioned above.
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As an ultrasound wave propagates through a medium,
absorption and scattering cause the attenuation of ultrasound energy; transformation of ultrasound energy to heat
is a result of this absorption [31,51]. The importance of
thermal effects increases with an increase in frequency
[34] and is also directly proportional to the ultrasound intensity and duty cycle [31]. Skin permeability and its diffusion coefficient were shown to be increased due to the
increase of skin temperature resulting from ultrasound
application [32]. In our current in vivo study, thermal
effects of ultrasound leading to temperature increase in
the cornea may have contributed to the increase in the
corneal permeability. In this study, the maximum change
in temperature was between 0°C and 6°C, with average
change of 3.2°C ± 1.8°C for all treatment cases. The corneal permeability to water was shown previously to increase as temperature increased from 24°C to 34°C [52].
Excessive ultrasound energy can thermally and mechanically damage the eye; therefore, U.S. Food and Drug
Administration (FDA) has enforced strict thermal and
mechanical index limits for ophthalmic applications [53].
FDA guidelines permitted using only ISPTA.3 of 17 mW/cm2
of acoustic energy for ocular application before Medical
Device Act of 1976 was passed, which was later changed
to ISPTA.3 of 50 mW/cm2 [54,55]. Thermal index (TI) is
ratio of device's total acoustic power to the power needed
to increase tissue's temperature by 1°C [53], and thermal
index limit for ocular application is TI < 1.0 [55-57]. We
believe that FDA regulations, in case of limits for intensities and temperature increase, are very restricted which
may cause a great constraint on using the ultrasound in
ocular drug delivery. More investigation using modeling
and long-term survival studies is required to determine all
potential adverse effects of ultrasound at our parameters
in the eye.
The eye is vulnerable to thermal damage from ultrasound exposure because the absence of blood flow in the
cornea and lens, both of which are avascular, results in
slower cooling as the heat is absorbed by these tissues
during ultrasound application [58,59]. Over-heating of the
lens is a major concern because it may cause cataract formation; however, Guy et al. indicated that the potential
risk would be generated if the temperature increases above
41°C [60]. Measuring the temperature of the lens was not
feasible in our current study; therefore, further modeling
and experimental investigations are needed to observe the
impact of ultrasound application at our proposed parameters on potential heat generation in the lens.
One of the main goals for this study is to investigate
the effectiveness of using ultrasound in ocular drug delivery and get some preliminary information regarding safety
of ultrasound application. Indeed, future studies will focus
on long-term survival experiments (up to 14 days) to
determine adverse effects of ultrasound in different eye
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tissues. Further, lens can get overheated and be damaged as a result of thermal effects of ultrasound application. The hyperthermia level of temperature increase
(41°C–43°C) did not reach in our study. The maximum
temperature increase during ultrasound application was
31°C, which was below the hyperthermia level; therefore,
we believed that the lens was not affected as a result of
ultrasound application. The maximal corneal temperature
in our experiments (31°C) was below the normal physiological temperature of rabbit cornea of 34°C [61] due to
the fact that the exposure to drug solution cooled down
the cornea. The maximal corneal temperatures observed
in this study were lower than the hyperthermia levels
(41°C–43°C); therefore, functional changes in the corneal epithelial cells due to heat were unlikely [58,62].
Modeling studies (that are currently ongoing) can be
helpful addressing the changes in the lens, retina, and
different tissues in the eye as a result of temperature increase during ultrasound application.
One of the key objectives of this study was to investigate
the damages in the cornea due to ultrasound application.
Putting a thermocouple inside the cornea would lead to
errors in measurement of cornea permeability, which was
another goal of this study, and would cause corneal damage, which interferes with the purpose of histology analysis
of corneal damages. However, measuring temperature inside the cornea may be more accurate. A modeling study
was completed that investigated the issue of temperature
increase in different eye tissues.
In vivo study was designed to investigate the drug delivery inside the eye while it is intact and inside the body.
Also dissecting the eye right after the experiment keeps it
fresh which decreases the chance of deterioration. The
greater intraocular pressure causes decrease in scleral
and corneal permeability. Rudnick et al. indicated that
the scleral permeability to small compounds is a weak
function of intraocular pressure and mostly depends on
molecular weight [63]. However, we did not measure
the intraocular pressure and its effect on drug penetration
through the cornea. Several animal studies indicated that
using HIFU could be a possible and effective technique to
reduce intraocular pressure [3]. Ultrasound has the potential for intraocular pressure reduction, which in our case
can have an effect on increasing ocular drug permeability;
however, this effect in not expected to be major based on
previous studies.
The same anesthesia method was performed in both
ultrasound treatment and sham treatment cases, so its
effects should not impact the study outcome that ultrasound application leads to increase the drug delivery
through the cornea. Usually, the depressants of the central
nervous system using general anesthetics will decrease intraocular pressure in relation with the depth of anesthesia,
and the type of drug can also be a factor effecting the
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change in intraocular pressure. However, ketamine causes
rising on intraocular pressure that is less than the decrease
caused by other general anesthesia [64]. There is a possibility that anesthesia can affect drug penetration through
the cornea, but this was not investigated in our studies.
The sham treatment underwent the same anesthesia
methods as ultrasound treatment, which allowed us to
observe the effects of ultrasound specifically.
The topical administration of a drug through the cornea,
especially for hydrophilic drugs, is a challenging task. Less
than 5% of the applied drug can penetrate through the
cornea because of the eye barriers [9,11,12]; for example,
the epithelium layer has lipophilic properties, which
makes it hard for the hydrophilic drug to penetrate into
the eye. In other words, we can state that both points
made here are important. Enhancement in the delivery
of dexamethasone sodium phosphate by 2–3 times is
considered clinically significant because this drug has
hydrophilic properties and its penetration through the
cornea is a challenge.
Even though the results from our in vivo study did not
show the temperature increase at the hyperthermia level
(41°C–43°C), a modeling study (currently in progress)
was designed to investigate the temperature changes in
the lens, retina, and different tissues in the eye. The results
from this modeling study (unpublished data) indicate that
the potential temperature increase was minimal and lower
than the hyperthermia level in all the eye tissues using
ultrasound application at parameters used in in vivo study.

Conclusions
Ultrasound may be used as an effective tool to enhance
ocular drug delivery. This study explored the feasibility
of using ultrasound for delivery of a clinically relevant
drug, dexamethasone sodium phosphate, in an in vivo
rabbit model. This study was designed using parameters
based on the results from our previously performed
in vitro studies. Increase of 2.8 times (p < 0.05) and 2.4
times (p < 0.05) in the drug penetration through the cornea was observed using ultrasound at 400 and 600 kHz,
respectively. Minor damage and structural changes were
present in the corneal epithelium of the ultrasoundtreated corneas. Further studies are needed to fully investigate the safety aspects of ultrasound application in
ocular drug delivery such as long-term monitoring of
recovery of corneal barrier properties and safety of ultrasound exposure in different eye tissues including the
lens and retina. It would also be of potential clinical
interest to perform studies involving ultrasound application for the enhancement of delivery of anti-fungal and
anti-viral ocular drugs currently used in treatment of different eye diseases such as keratitis, scleritis, and herpetic
eye disease.
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